We report a 59-year-old man with diabetic lipemia associated with acute pancreatitis. The patient was being treated for type 2 diabetes, but his glycemic control was poor. Although his insulin secretory activity was p...We report a 59-year-old man with diabetic lipemia associated with acute pancreatitis. The patient was being treated for type 2 diabetes, but his glycemic control was poor. Although his insulin secretory activity was preserved, acute pancreatitis developed because of hypertriglyceridemia and the patient had type V hyperlipidemia. After hospitalization, his hyperlipidemia and hyperglycemia improved in response to insulin infusion and hydration. It is well known that diabetic lipemia is caused by type 1 diabetes, but is rare in type 2 diabetes. Insulin resistance, as well as insulin deficiency, might play a role in the development of diabetic lipemia.展开更多
Mesenchymal stem cells(MSCs)have abilities to mediate tissue protection through mechanisms of antiapoptosis,anti-oxidative stress and anti-fibrosis as well as tissue regeneration through mechanisms of cell proliferati...Mesenchymal stem cells(MSCs)have abilities to mediate tissue protection through mechanisms of antiapoptosis,anti-oxidative stress and anti-fibrosis as well as tissue regeneration through mechanisms of cell proliferation,differentiation and angiogenesis.These effects by MSCs are mediated by a variety of factors,including growth factors,cytokines and extracellular vesicles(EVs).Among these factors,EVs,containing proteins,mRNA and microRNAs(miRNA),may carry their contents into distant tissues with high stability.Therefore,the treatment with MSC-derived EVs may be promising as‘natural’drug delivery systems(DDS).Especially,the treatment of MSCderived EVs with the manipulation of specific miRNAs expression has been reported to be beneficial under a variety of diseases and tissue injuries.The overexpression of specific miRNAs in the EVs might be through pre-loading method using the gene editing system by plasmid vector or post-loading method to load miRNA mimics into EVs by electroporation or calcium chloride-mediated transfection.Despite current several challenges for clinical use,it should open the next era of regenerative medicine for a variety of diseases.In this article,we highlight the therapeutic potential of MSC-derived EVs as‘natural’DDS and current challenges.展开更多
Aim: We aimed to investigate whether the agonists for liver X receptor (LXR) ameliorate lupus-like phenotypes in mice mediated by the clearance of apoptotic cells, and compare with peroxisome proliferator-activated re...Aim: We aimed to investigate whether the agonists for liver X receptor (LXR) ameliorate lupus-like phenotypes in mice mediated by the clearance of apoptotic cells, and compare with peroxisome proliferator-activated receptor (PPAR) γ plus PPARδ agonists, which also facilitate the clearance of apoptotic cells and exert anti-inflammatory effects in systemic lupus erythematosus (SLE). Methods: We investigated the efficacy of LXR agonist (GW3965) or dual treatment of PPARγ (pioglitazone) and PPARδ (GW0742) agonists in SLE animal models, female MRL/MpJ-Fas/J mice and BALB/cAJcl mice treated with pristane. The data were analyzed with one-way analysis of variance and Tukey’s honestly significant difference tests. Results: The treatment with LXR or PPARγ/δ agonists did not significantly alter the swelling of lymph nodes, ds-DNA production, albuminuria, histological score of glomerular lesions, and mRNA expression of target genes including Abca1, C1qa, Icam1, Mertk and Tnf. Conclusion: LXR or PPARγ/δ agonists targeting the impaired clearance for apoptosis cells may not be efficient in the remission induction therapy in SLE.展开更多
文摘We report a 59-year-old man with diabetic lipemia associated with acute pancreatitis. The patient was being treated for type 2 diabetes, but his glycemic control was poor. Although his insulin secretory activity was preserved, acute pancreatitis developed because of hypertriglyceridemia and the patient had type V hyperlipidemia. After hospitalization, his hyperlipidemia and hyperglycemia improved in response to insulin infusion and hydration. It is well known that diabetic lipemia is caused by type 1 diabetes, but is rare in type 2 diabetes. Insulin resistance, as well as insulin deficiency, might play a role in the development of diabetic lipemia.
文摘Mesenchymal stem cells(MSCs)have abilities to mediate tissue protection through mechanisms of antiapoptosis,anti-oxidative stress and anti-fibrosis as well as tissue regeneration through mechanisms of cell proliferation,differentiation and angiogenesis.These effects by MSCs are mediated by a variety of factors,including growth factors,cytokines and extracellular vesicles(EVs).Among these factors,EVs,containing proteins,mRNA and microRNAs(miRNA),may carry their contents into distant tissues with high stability.Therefore,the treatment with MSC-derived EVs may be promising as‘natural’drug delivery systems(DDS).Especially,the treatment of MSCderived EVs with the manipulation of specific miRNAs expression has been reported to be beneficial under a variety of diseases and tissue injuries.The overexpression of specific miRNAs in the EVs might be through pre-loading method using the gene editing system by plasmid vector or post-loading method to load miRNA mimics into EVs by electroporation or calcium chloride-mediated transfection.Despite current several challenges for clinical use,it should open the next era of regenerative medicine for a variety of diseases.In this article,we highlight the therapeutic potential of MSC-derived EVs as‘natural’DDS and current challenges.
文摘Aim: We aimed to investigate whether the agonists for liver X receptor (LXR) ameliorate lupus-like phenotypes in mice mediated by the clearance of apoptotic cells, and compare with peroxisome proliferator-activated receptor (PPAR) γ plus PPARδ agonists, which also facilitate the clearance of apoptotic cells and exert anti-inflammatory effects in systemic lupus erythematosus (SLE). Methods: We investigated the efficacy of LXR agonist (GW3965) or dual treatment of PPARγ (pioglitazone) and PPARδ (GW0742) agonists in SLE animal models, female MRL/MpJ-Fas/J mice and BALB/cAJcl mice treated with pristane. The data were analyzed with one-way analysis of variance and Tukey’s honestly significant difference tests. Results: The treatment with LXR or PPARγ/δ agonists did not significantly alter the swelling of lymph nodes, ds-DNA production, albuminuria, histological score of glomerular lesions, and mRNA expression of target genes including Abca1, C1qa, Icam1, Mertk and Tnf. Conclusion: LXR or PPARγ/δ agonists targeting the impaired clearance for apoptosis cells may not be efficient in the remission induction therapy in SLE.
